The Result of Combined Modality Treatment for Limited Stage Small Cell Lung Cancer.
- Author:
Jae Cheol KIM
1
;
Yang Suk JANG
;
Samuel RYU
;
In Kyu PARK
Author Information
1. Department of Therapeutic Radiology, Kyungpook National University Hospital, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
Lung cancer;
Small cell Carcinoma;
Limited stage;
Combined modality therapy
- MeSH:
Carcinoma, Small Cell;
Combined Modality Therapy;
Cranial Irradiation;
Drug Therapy;
Drug Therapy, Combination;
Female;
Gyeongsangbuk-do;
Humans;
Lung Neoplasms;
Phosphopyruvate Hydratase;
Radiation Oncology;
Small Cell Lung Carcinoma*;
Survival Rate
- From:Journal of the Korean Society for Therapeutic Radiology
1989;7(2):205-212
- CountryRepublic of Korea
- Language:English
-
Abstract:
From July 1984 to September 1988, 27 patients with limited stage small cell lung cancer were treated with combined modality(combination chemotherapy Plus radiotherapy) at the Department of Therapeutic Radiology in Kyungpook National University Hospital. Of the 27 patients, 19(70%) achieved a complete response, 6(22%) a partial response, and 2(8%) no response. Female, performance status HO, serum enolase level below 30ng/ml, radiation dose over 4500 cGy, and 4 or more cycles of chemotherapy had a favorable effect on the rates of complete response, although there were no statistical differences according to the variables. Median survival time was 10 Months and overall 1- and 2-year survival rates were 40.7% and 12.2%, respectively. Complete response(p<0.05), performance status HO(p<0.05), 4 or more cycles of chemotherapy(p<0.05), and radiation dose over 4500 cGy had a significantly favorable effect on 2-year survival rate. Prophylactic cranial irradiation or sex had no effect on survival. The results of this study suggest that radiation treatment should be combined with combination chemotherapy in the therapeutic strategy of SCLC of limited stage.
